

Antibody Technologies
Available for Licensing and co-development
<http://techtransfer.cancer.gov/availabletechnologies>

Lead Inventor	Title	Therapeutic Area	Reference #
Peter Choyke	Photoactivable Dye Compounds for Conjugate Formation and Methods of Making and Using the Same	Oncology	TAB-5086 E-137-2024-0
Mitchell Ho	Camel VHH Nanobodies Bind the S2 Subunit of SARS-CoV-2 and Broadly Neutralize Variants including Omicron	Infectious Diseases Immunology	TAB-3960 E-129-2023-0
Mitchell Ho	Single Domain Antibodies targeting HPV E6/E7 Oncogenic Peptide/MHC complexes	Oncology	TAB-4211 E-169-2022-0
Jeffrey Gildersleeve	A Human Monoclonal Antibody Against Deacetylated PNAG for Use as an Antimicrobial Agent	Infectious Diseases	TAB-3896 E-075-2022-0
Ira Pastan	Mab 1586 blocks Mesothelin Shedding and Makes Very Active CAR-T Cell and BITE	Oncology	TAB-4322 E-033-2022-0
Mitchell Ho	Single Domain Antibodies Targeting the S2 Subunit of SARS-CoV-2 Spike Protein	Infectious Diseases, Immunology	TAB-4357 E-204-2021-0
Mitchell Ho	Cross Species Single Domain Antibodies Targeting PD-L1 for Treating Solid Tumors	Solid tumors expressing PD-L1	TAB-3949 E-118-2021-0
Mitchell Ho	Nanobodies Neutralizing Lassa Virus	Infectious Diseases	TAB-4029 E-099-2021-0
Mitchell Ho	Single Domain Antibodies (Nanobodies) Targeting SARS-CoV-2 for treating COVID-19	COVID-19 Therapeutic	TAB-3882 E-253-2020-0

Antibody Technologies
Available for Licensing and co-development
<http://techtransfer.cancer.gov/availabletechnologies>

Mitchell Ho	High Affinity Nanobodies Targeting B7-H3 (CD276) for Treating Solid Tumors	Solid tumor	TAB-4281 E-185-2019-0
Brad St. Croix	Development of Next Generation Antibody Drug Conjugates (ADCs) Against CD276	Endothelial tumor	TAB-4275 E-145-2019-0

Antibody Technologies
Available for Licensing and co-development
<http://techtransfer.cancer.gov/availabletechnologies>

David FitzGerald	EGFRvIII Antibodies for the Treatment of Human Cancer	EGFRvIII-expressing cancers	TAB-3947 E-103-2019-0
Mitchell Ho	High Affinity Cross Species Single Domain Antibodies Targeting Mesothelin	Solid tumors over-expressing Mesothelin	TAB-4332 E-040-2019-0
Mitchell Ho	High Affinity Monoclonal Antibodies Targeting Glypican-1	Solid tumors over-expressing GPC1	TAB-4107 E-028-2019-0
Mitchell Ho	High Affinity Monoclonal Antibodies Targeting Glypican-2 for Treating Childhood Cancers	Neuroblastoma	TAB-4215 E-198-2018-0
Dimiter Dimitrov	Improved CD22 Binders for Effective Immunotherapy Against Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)	Antibody drug conjugates against relapsed / refractory ALL	TAB-3892 E-161-2018-0
Ira Pastan	New Class of Immunotoxins with Extended Half-Life and High Anti-Tumor Activity	Hematological cancers	TAB-3880 E-231-2017-0
Ira Pastan	Monoclonal Antibodies and Immunoconjugates Directed to the Non-Shed Portion ("Stalk") of Mesothelin are Excellent Candidates for Developing Therapeutic Agents	Mesothelin	TAB-4371 E-106-2017-0
Dimiter Dimitrov	Fully Human Antibody Targeting Tumor Necrosis Factor Receptor Type 2 (TNFR2) for Cancer Immunotherapy	Immunotherapy	TAB-4190 E-065-2017-0
Dimiter Dimitrov	Antibodies and CARs Targeting FLT3 for the Treatment of Acute Myeloid Leukemia and Acute Lymphoid Leukemia	Cancers expressing FLT3	TAB-4105 E-014-2017-0

Antibody Technologies
Available for Licensing and co-development
<http://techtransfer.cancer.gov/availabletechnologies>

Martin Schnermann	Near-IR Light-Cleavable Antibody Conjugates and Conjugate Precursors	Targeted cancer therapy	TAB-4000 E-245-2016-0
Mitchell Ho	Human Monoclonal Antibodies Targeting Glypican-2 in Neuroblastoma	Neuroblastoma	TAB-4233 E-211-2016-0
Simone Difilippantonio	Agonist Epitopes for the Development of a Human Papillomavirus (HPV) Therapeutic Vaccine	HPV	TAB-4384 E-169-2016-0
Barry O'Keefe	A Triple Combination HIV Microbicide	HIV-1, HSV, HCV	TAB-4034 E-137-2016-0
Apurva Srivastava	Anti-Py1235-Met Immunological Binding Reagent as Cancer Diagnostic	Detection of pMET-Y1235 in biological samples	TAB-4427 E-130-2016-0
Javed Khan	Fibroblast Growth Factor Receptor 4 (FGFR4) Monoclonal Antibodies and Methods of Their Use (BiTE)	Cancers expressing FGFR4	TAB-3912 E-264-2015-0
Scott Durum	IL7R α -Specific Antibody for Treating Acute Lymphoblastic Leukemia (ALL)	Blood cancers, autoimmune disorders	TAB-4298 E-247-2015-0
Dimiter Dimitrov	Therapeutic antibody-drug conjugates targeting CD56-positive cancers	Neuroblastoma	TAB-3908 E-221-2015-0
Dimiter Dimitrov	Fusion Proteins as HIV-1 Entry Inhibitors	HIV-1	TAB-4027 E-086-2015-0

Antibody Technologies
Available for Licensing and co-development
<http://techtransfer.cancer.gov/availabletechnologies>

Thomas D. Pfister	Anti-CD133 Monoclonal Antibodies as Cancer Therapeutics	Cancer, immune system and inflammation	TAB-4254 E-025-2015-0
David D. Roberts	Use of Anti-CD47 Antibodies for the Treatment of Cancer	Breast cancer and other cancers	TAB-4312 E-263-2014-0
Dimiter Dimitrov	Fully Human Antibodies and Antibody Drug Conjugates Targeting CD276 (B7-H3) for the Treatment of Cancer	Endothelial tumors	TAB-4393 E-250-2014-0
Stanislaw J. Kaczmarczyk	Cancer Immunotherapy Using Virus-like Particles	Cancer	TAB-4013 E-050-2014-0
Jeffrey Baron	Monoclonal Antibody Fragments for Targeting Therapeutics to Growth Plate Cartilage	Cartilage disorders	TAB-4015 E-003-2014-0
Dimiter Dimitrov	Human Antibodies Against Middle East Respiratory Syndrome Coronavirus	Treatment for MERS-CoV infection	TAB-4410 E-002-2014-0
James Doroshov	A Rabbit Anti-pT1989 ATR Monoclonal Antibody for Use in Immunoassays	Detection of pATR-T1989 in biological samples	TAB-4103 E-001-2014-0
Dimiter Dimitrov	Her2 Monoclonal Antibodies, Antibody Drug Conjugates as Cancer Therapeutics	Her2 positive cancers	TAB-3995 E-351-2013-0
Dimiter Dimitrov	Fully Human Antibodies and Antibody Drug Conjugates Targeting Tumor Endothelial Marker 8 (TEM8) for the Treatment of Cancer	Solid tumors over-expressing TEM8	TAB-4316 E-344-2013-0



Antibody Technologies
Available for Licensing and co-development
<http://techtransfer.cancer.gov/availabletechnologies>

Contact:

Michael L. Salgaller, PhD | Supervisory Specialist | Email: Michael.salgaller@nih.gov | Phone: (240) 276-5476

Joseph M. Conrad III, PhD, JD | Senior Technology Transfer & Marketing Specialist |

Email: joseph.conrad@nih.gov | Phone: (240) 276-5495